Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction

Dig Dis Sci. 1995 Sep;40(9):1892-901. doi: 10.1007/BF02208652.


Treatment of chronic intestinal pseudoobstruction with prokinetic agents has been disappointing. Our study was designed to determine if octreotide and erythromycin would provide sustained relief from nausea, abdominal pain, and bloating in pseudoobstruction. Using gastrointestinal manometry, quantitative parameters of the activity front of the migrating motor complex at baseline and after prokinetic therapy with erythromycin and octreotide were determined in 14 patients with intestinal pseudoobstruction who had nausea, abdominal pain, and bloating. Patients were treated with erythromycin and octreotide for 20-33 weeks. Octreotide increased the frequency, duration, and motility index of activity fronts (AFs) from 1.2 +/- 0.3 AFs/4 hr, 2.7 +/- 0.7 min, and 85 +/- 23 min mm Hg to 4.1 +/- 0.8 AFs/4 hr, 5.5 +/- 0.7 min, and 152 +/- 24 min mm Hg, respectively (P < 0.05). Antral activity was decreased from 63 +/- 14 to 23 +/- 8% by octreotide (P < 0.05). Erythromycin induced antral activity; however, small intestinal motor activity was suppressed. While on erythromycin and octreotide, five patients had long-term improvement of nausea and abdominal pain. All responders had at least 5 AFs/4 hr induced by octreotide. We conclude that octreotide and erythromycin relieve abdominal pain and nausea in pseudoobstruction. Patients who have at least 5 AFs/4 hr after octreotide administration are most likely to clinically respond.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Drug Therapy, Combination
  • Erythromycin / therapeutic use*
  • Female
  • Gastrointestinal Agents / therapeutic use*
  • Gastrointestinal Motility / drug effects
  • Humans
  • Intestinal Pseudo-Obstruction / drug therapy*
  • Intestinal Pseudo-Obstruction / etiology
  • Male
  • Manometry
  • Middle Aged
  • Octreotide / therapeutic use*
  • Prospective Studies
  • Scleroderma, Systemic / complications*


  • Gastrointestinal Agents
  • Erythromycin
  • Octreotide